Shopping Cart
- Remove All
- Your shopping cart is currently empty
INF 195 is an inflammasome NLRP3 inhibitor that inhibits NLRP3-driven macrophage pyroptosis and IL-1β release. INF 195 reduces isoproterenol-induced hypertrophy in H9c2 rat myoblasts and can be used to study myocardial ischemia and myocardial infarction.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $74 | In Stock | |
10 mg | $116 | In Stock | |
25 mg | $232 | In Stock | |
50 mg | $380 | In Stock | |
100 mg | $600 | In Stock |
Description | INF 195 is an inflammasome NLRP3 inhibitor that inhibits NLRP3-driven macrophage pyroptosis and IL-1β release. INF 195 reduces isoproterenol-induced hypertrophy in H9c2 rat myoblasts and can be used to study myocardial ischemia and myocardial infarction. |
In vitro | INF 195 (0.1-100 μM, 72 hours) was able to inhibit macrophage pyroptosis and IL-1β release driven by NLRP3. At lower doses (5-10 μM, 10 min), INF 195 was able to reduce the infarct zone in isolated mouse hearts and effectively prevented myocardial ischemia/reperfusion injury.INF 195 (10 μM), as an ethyl ester precursor of the active metabolite 3-(3-(2-chlorophenyl)propanoyl)piperidine-1-carboxylic acid, was able to penetrate into H9c2 cardiomyoblasts, and hydrolyzed intracellularly to this active form. [1] |
Alias | INF-195, INF195 |
Molecular Weight | 323.81 |
Formula | C17H22ClNO3 |
Cas No. | 1211379-56-4 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 150 mg/mL (463.23 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.